MADISON, Wis.--(BUSINESS WIRE)--
Exact Sciences Corp. (Nasdaq: EXAS) today announced that Kevin T.
Conroy, the company’s chairman, president and chief executive, will make
Exact Sciences’ presentation at the 2016 J.P. Morgan Healthcare
Conference in San Francisco at 8 a.m. PT on Thursday, Jan. 14, 2016.
A live webcast of the presentation and Q&A session will be available
through the company’s website at www.exactsciences.com.
An archive of the webcast will be available following the conclusion of
the presentation and Q&A session.
About Exact Sciences Corp.
Exact Sciences Corp. is a molecular diagnostics company focused on
gastrointestinal cancers. The company’s noninvasive colorectal cancer
screening test, Cologuard, is the first and only FDA-approved
stool-based DNA test. Stool-based DNA technology is included in the
colorectal cancer screening guidelines of the American Cancer Society
and the U.S. Multi-Society Task Force on Colorectal Cancer. For more
information, please visit the company’s website at www.exactsciences.com.
Certain statements made in this news release contain forward-looking
statements within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended that are intended to be covered by the "safe harbor"
created by those sections. Forward-looking statements can generally be
identified by the use of forward-looking terms such as "believe,"
"expect," "may," "will," "should," "could," "seek," "intend," "plan,"
"estimate," "anticipate" or other comparable terms. All statements other
than statements of historical facts included in this news release
regarding our strategies, prospects, financial condition, operations,
costs, plans and objectives are forward-looking statements. Examples of
forward-looking statements include, among others, statements we make
regarding expected numbers of completed and reported Cologuard tests,
anticipated patient compliance rates, expected future operating results,
anticipated results of our sales and marketing efforts, expectations
concerning payor reimbursement and the anticipated results of our
product development efforts. Forward-looking statements are neither
historical facts nor assurances of future performance. Instead, they are
based only on our current beliefs, expectations and assumptions
regarding the future of our business, future plans and strategies,
projections, anticipated events and trends, the economy and other future
conditions. Because forward-looking statements relate to the future,
they are subject to inherent uncertainties, risks and changes in
circumstances that are difficult to predict and many of which are
outside of our control. Our actual results and financial condition may
differ materially from those indicated in the forward-looking
statements. Therefore, you should not rely on any of these
forward-looking statements. Important factors that could cause our
actual results and financial condition to differ materially from those
indicated in the forward-looking statements include, among others, the
following: our ability to successfully and profitably market our
products; the acceptance of our products by patients and health care
providers; the willingness of health insurance companies and other
payors to reimburse us for our performance of the Cologuard test; the
amount and nature of competition from other cancer screening products
and procedures; our ability to maintain regulatory approvals and comply
with applicable regulations; our success establishing and maintaining
collaborative and licensing arrangements; recommendations and/or
guidelines issued by the U.S. Preventive Services Task Force, the
American Cancer Society, or other organizations regarding cancer
screening or our products and services; our ability to successfully
develop new products; and the other risks and uncertainties described in
the Risk Factors and in Management's Discussion and Analysis of
Financial Condition and Results of Operations sections of our most
recently filed Annual Report on Form 10-K and our subsequently filed
Quarterly Reports on Form 10-Q. We undertake no obligation to publicly
update any forward-looking statement, whether written or oral, that may
be made from time to time, whether as a result of new information,
future developments or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151222005399/en/
Source: Exact Sciences Corp.